Waters Corporation, a Delaware-based company, has filed a Form 8-K with the Securities and Exchange Commission (SEC) on March 16, 2026, detailing its acquisition of the former Biosciences and Diagnostic Solutions business from Becton, Dickinson and Company (BD). This acquisition, completed on February 9, 2026, is part of a strategic move to enhance Waters' portfolio in the life sciences sector. The filing includes unaudited condensed combined financial statements for the SpinCo Business as of December 31, 2025, and September 30, 2025, along with management's discussion and analysis of financial conditions and results of operations for the fiscal years ended September 30, 2025, 2024, and 2023. The documents indicate that the SpinCo Business generated revenues of $766 million in the three months ended December 31, 2025, compared to $834 million in the same period of the previous year. The filing also outlines the operational integration plans and the expected synergies from the merger, which are anticipated to enhance Waters' market position and operational efficiency. The acquisition is expected to provide Waters with a broader range of products and services, particularly in microbiology and infectious disease diagnostics, which are critical areas in the current healthcare landscape. The financial statements reveal that Waters is committed to maintaining robust governance controls and operational execution as it integrates the new business unit. This strategic acquisition is seen as a positive step for Waters, potentially leading to improved financial performance and market competitiveness in the life sciences industry.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.